Share This:
https://ntp.niehs.nih.gov/go/15403

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04
Route: GAVAGE                                                                                                     Time: 13:18:26

                                                     31 WEEK SSAC FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFBINARYMIX

       Lock Date:  03/27/02

       Cage Range:  All

       Reasons For Removal:    25017 Scheduled Sacrifice

       Removal Date Range:     04/14/99 - 04/15/99

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 002    10 NG / 10 UG
                               Include 003    100 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 007    1000 NG/1000 UG






























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 13:18:26    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           86           98           98           98                        
                                                                                                                                    
  Scheduled Sacrifice                                 16           10           16           16           16                        
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
                                                                                                                                    
  Animals Examined Microscopically                    10           10           10           10           10                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (10)         (10)         (10)         (10)         (10)                      
      Clear Cell Focus                                              1 (10%)                                                         
      Fatty Change, Diffuse                                                                   1 (10%)     10 (100%)                 
      Inflammation                                    10 (100%)    10 (100%)    10 (100%)    10 (100%)    10 (100%)                 
      Mixed Cell Focus                                 1 (10%)                   2 (20%)      3 (30%)      2 (20%)                  
      Mixed Cell Focus, Multiple                       1 (10%)      1 (10%)      1 (10%)      3 (30%)      3 (30%)                  
      Pigmentation                                                               3 (30%)     10 (100%)    10 (100%)                 
      Toxic Hepatopathy                                                                                    5 (50%)                  
      Bile Duct, Hyperplasia                                                                  1 (10%)      2 (20%)                  
      Bile Duct, Inflammation, Chronic Active,                                                                                      
         Focal                                                                                             1 (10%)                  
      Hepatocyte, Hypertrophy                                       3 (30%)      5 (50%)     10 (100%)    10 (100%)                 
      Hepatocyte, Multinucleated                                                                           9 (90%)                  
   Pancreas                                           (10)         (10)         (10)         (10)         (10)                      
      Basophilic Focus                                                                        1 (10%)                               
      Inflammation, Chronic Active                     1 (10%)      1 (10%)                   1 (10%)                               
      Acinus, Atrophy                                  1 (10%)      1 (10%)                   1 (10%)                               
      Acinus, Vacuolization Cytoplasmic                                                                    3 (30%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (10)         (10)         (10)         (10)         (10)                      
      Degeneration, Cystic                                          1 (10%)      1 (10%)                                            
      Hyperplasia                                                                             1 (10%)      2 (20%)                  
      Hypertrophy                                      3 (30%)      2 (20%)      2 (20%)      4 (40%)      1 (10%)                  
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 13:18:26    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
      Vacuolization Cytoplasmic                                                                            1 (10%)                  
   Thyroid Gland                                      (10)         (10)         (10)         (10)         (10)                      
      Follicular Cell, Hypertrophy                                  5 (50%)      5 (50%)      7 (70%)      8 (80%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (10)         (10)         (10)         (10)         (10)                      
      Atrophy                                          6 (60%)      7 (70%)      9 (90%)     10 (100%)     6 (60%)                  
   Uterus                                             (10)         (10)         (10)         (10)         (10)                      
      Inflammation, Suppurative                        1 (10%)      1 (10%)                                                         
      Metaplasia, Squamous                             6 (60%)      7 (70%)      5 (50%)      9 (90%)      4 (40%)                  
      Endometrium, Hyperplasia, Cystic                              1 (10%)      1 (10%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                                                   (1)                                                 
      Mediastinal, Inflammation, Granulomatous                                   1 (100%)                                           
   Spleen                                             (10)                                                                          
      Pigmentation                                    10 (100%)                                                                     
   Thymus                                             (10)         (10)         (10)         (10)         (10)                      
      Atrophy                                          6 (60%)      5 (50%)      6 (60%)      7 (70%)     10 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 13:18:26    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (10)         (10)         (10)         (10)         (10)                      
      Hemorrhage                                                                              1 (10%)                               
      Infiltration Cellular, Histiocyte                2 (20%)      1 (10%)                   1 (10%)      4 (40%)                  
      Inflammation                                                  1 (10%)                                                         
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------